Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Summit Therapeutics PLC (SMMT : NSDQ)

• Company Description    Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom. Number of Employees: 159

• Price / Volume Information    Yesterday's Closing Price: $25.00 Daily Weekly Monthly 20 Day Moving Average: 3,654,230 shares Shares Outstanding: 742.67 (millions) Market Capitalization: $18,566.65 (millions) Beta: -1.01 52 Week High: $36.91 52 Week Low: $8.36 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 24.01% 19.76% 12 Week 1.58% -14.27% Year To Date 40.10% 35.82%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 601 BRICKELL KEY DRIVE SUITE 1000 - MIAMI,FL 33131 USA ph: 305-203-2034 fax: 44-12-3544-3999 investors@smmttx.com http://www.smmttx.com

• General Corporate Information    Officers Robert W. Duggan - Co-Chief Executive Officer and Executive Chairman Mahkam Zanganeh - Co-Chief Executive Officer; President and Director Manmeet S. Soni - Chief Operating Officer; Chief Financial Officer a Robert F. Booth - Director Alessandra Cesano - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 86627T108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/05/25 Share - Related Items Shares Outstanding: 742.67 Most Recent Split Date: (:1) Beta: -1.01 Market Capitalization: $18,566.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.41 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 53.92 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -80.00% vs. Previous Quarter: -12.50% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -62.87 12/31/24 - -69.72 ROA 06/30/25 - - 03/31/25 - -51.61 12/31/24 - -51.01 Current Ratio 06/30/25 - - 03/31/25 - 10.63 12/31/24 - 10.15 Quick Ratio 06/30/25 - - 03/31/25 - 10.63 12/31/24 - 10.15 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.46 12/31/24 - 0.53 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©